Abivax S.A. (ABVX) Stock Score, Valuation & Financial Research

Abivax S.A. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ABVX

Abivax S.A. does not currently have a complete Wall Street Score. The stored market price is USD 99.02. These figures are a research snapshot, not a buy or sell recommendation.

What Abivax S.A. does

Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Abivax is a clinical-stage biotechnology company that focuses on the development of therapeutic candidates for chronic inflammatory diseases. The company does not currently generate revenue from product sales and relies on capital raises and potential future licensing or collaboration agreements to fund its research and development activities.

Products and services

  • The company's primary product candidate is obefazimod, a small molecule drug currently in clinical development for the treatment of ulcerative colitis and other inflammatory conditions.

Brands and product families

  • Obefazimod — Lead clinical-stage drug candidate for inflammatory diseases. Source

Customer types

Healthcare providers and patients (potential future market).

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs) — The company relies on unnamed third-party service providers for clinical trial management, drug substance manufacturing, and drug product formulation. Source

Competitors and product-market comparisons

  • Pharmaceutical and biotechnology companies — Companies developing therapies for inflammatory bowel diseases and other autoimmune conditions, including those with approved products or competing clinical-stage candidates. Source

Business strengths to evaluate

  • Clinical progress of lead candidate obefazimod Source

Business risks and research considerations

  • History of operating losses and dependence on additional financing Source
  • Risks associated with clinical trial outcomes and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ABVX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 99.02
Market capitalization:
7.27B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -573.71M
Free cash flow:
USD -176.71M
Cash:
USD 439.99M
Total debt:
USD 1.37M
EPS:
USD -7.55

What stands out

  • Free cash flow is USD -176.71M, negative for the stored period.
  • The balance sheet shows USD 439.99M of cash versus USD 1.37M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 438.62M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ABVX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ABVX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ABVX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ABVX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of ABVX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ABVX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.